Alector Inc (STU:0Z2)
€ 3.98 -0.02 (-0.5%) Market Cap: 391.41 Mil Enterprise Value: -93.80 Mil PE Ratio: 0 PB Ratio: 2.37 GF Score: 62/100

Alector, Inc. - Special Call Transcript

Dec 13, 2019 / 01:00PM GMT
Release Date Price: €17.61 (-0.26%)
Sabah Oney
Alector, Inc. - Chief Business Officer

Good morning, everybody. Thank you all for being here. We're very appreciative of all of you that are here in person in a packed room and for those of you that are dialing in, really appreciate especially potentially from West Coast, 5 am in the morning. So let's get this started. I'm Sabah, I'm the Chief Business Officer at Alector, and I've been with the team for about 4 years now, and welcome to our first, and what we hope to be, Annual Research and Development Day.

I will be your MC. I'll kick things off. And quickly, I'll be handing it over to Arnon, who's our CEO and Co-Founder.

Really quickly. The speakers today are Arnon; Robert Paul, who is our Chief Medical Officer, I'll do a quick section on the corporate strategy. And then we have 3 key opinion leaders in neurodegeneration. Dr. Masellis from Sunnybrook Health Sciences Centre; Dr. Bradshaw from Columbia University; and Dr. Cruchaga from Washington University in St. Louis. They will be going over specific sections in our presentation as well and giving you the research

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot